The PROMAGEN Study: Weight loss and Cholesterol
This randomised, double-blind, placebo controlled study aimed to assess the effect of 6-months supplementation with the Lab4P probiotic on body weight and well-being in healthy overweight and obese individuals.
Body weight, BMI and Waist Circumference
Lab4P probiotic supplementation (Group 2) resulted in significant weight loss compared to Group 1 (Fig. 1)
– A difference of -1.3kg in the total population (****P< 0.0001)
– A difference of -1.4kg in the overweight participants (****P< 0.0001)
– A difference of -1.76kg in the over 50 year olds (***P< 0.001)
– A difference of -2.1kg in the hypercholesteraemic participants (****P< 0.0001)
Significant reductions in BMI, waist circumference and waist-to-height ratio were also observed in each of the above populations.
Greater rates of weight loss were observed in the overweight participants compared to the obese (1.9% vs. 1.2% reduction) and in women compared to men (1.6 vs. 1.4% reduction).
Plasma Cholesterol levels in hypercholesteraemic participants (total cholesterol > 6.2 mmol/l)
A significant reduction of 17.6% in the plasma levels of atherogenic small dense LDL-cholesterol (sdLDL-C) was observed in hypercholesterolaemic participants taking Lab4P probiotics (Group 2a) compared to Group 1a (*P<0.05). The plasma LDL-C levels were reduced by 6.59%.
Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?